VENIXXA
Natural health product licensed in Canada
- Licence holder
- Servier Canada Inc.
- NPN or DIN-HM
- 80078681
- Status
- Active licence
- Licence date
- 23 June 2017
- Revision date
- Not provided
- Form
- Suspension
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Bioflavonoïdes d'agrumes Source : Bioflavonoïdes d'agrumes Potency : 90 % Diosmin | 1,000 milligramme | Not calculated |
| Bioflavonoïdes d'agrumes Source : Bioflavonoïdes d'agrumes Potency : 10 % Flavonoids expressed as hesperidin | Not specified | Not calculated |
Non-medicinal ingredients
4-O-bêta-D-galactopyranosyl-D-glucitol, Eau purifiée, Gomme de xanthane, Benzoate de sodium, Saveur d'orange, Acide citrique
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Portion(s) | 1 Tous les jours |
| Adultes | Not specified | 1 Portion(s) | minimum: 2 Tous les jours ; maximum: 3 Tous les jours |
Uses authorised in Canada
Helps to reduce lower leg oedema associated with mild-to moderate chronic venous disease. Helps to relieve symptoms of mild-to moderate chronic venous disease such as varicose veins, pain in the legs, sensation of heaviness, sensation of swelling, fatigue, discomfort. Limits progression of chronic venous disease. Helps to reduce signs and symptoms associated with hemorrhoids, such as pain, bleeding, itching (pruritus), swelling (oedema), anal discharge, discomfort, inflammation (proctitis), redness (erythema), and sensation of needing to pass stools (tenesmus). Helps to reduce the duration, intensity and recurrence of acute hemorrhoidal episodes.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
Hypersensitivity/ allergy, gastrointestinal discomfort, dizziness, headache, malaise and skin reactions have been known to occur; in which case, discontinue use and consult a health care practitioner.
- Précautions et mises en garde
Treatment should be avoided during pregnancy and breastfeeding. If you are taking prescription medication, consult a health care practitioner prior to use. For Hemorrhoidial Disease : If symptoms persist or worsen, or if acute hemorrhoidal episode persists after 7 days of use, consult a healthcare practitioner. For Hemorrhoidial Disease : If hemorrhoids are accompanied by rectal bleeding (bloody stools sometimes look like black tar), or if you are experience a change in bowel habits, consult a health care practitioner. For Chronic Venous Disease: If you suffer, or experience inflammation of the skin, thrombophlebitis or subcutaneous induration, severe pain, ulcers, sudden swelling of one or both legs, cardiac or renal insufficiency or disorder, consult a health care practitioner prior to use. For Chronic Venous Disease: If symptoms persist or worsen, consult a health care practitioner.
Source
Official Health Canada record, licence 80078681
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.